Acquired Immunodeficiency Syndrome disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

AIDS MCID: ACQ007 MIFTS: 60	Acquired Immunodeficiency Syndrome (AIDS) Categories: Blood diseases, Cancer diseases, Immune diseases, Infectious diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Acquired Immunodeficiency Syndrome

MalaCards integrated aliases for Acquired Immunodeficiency Syndrome:

Name: Acquired Immunodeficiency Syndrome ¹¹ ⁴³ ¹⁴ ⁷¹

Acquired Immune Deficiency Syndrome ¹¹ ² ¹⁴

Aids ¹¹ ⁴⁷

Acquired Immunodeficiency Due to Protein Loss ³³

Acquired Immune Deficiency ¹¹

Acquired Immunodeficiency ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases Cancer diseases
Anatomical: Immune diseases Blood diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Certain infectious and parasitic diseases

Human immunodeficiency virus [HIV] disease

Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases

ICD11: ³³

Diseases of the immune system

Acquired immunodeficiencies

Acquired immunodeficiencies, unspecified

Acquired immunodeficiency due to loss of immunoglobulin

Other specified acquired immunodeficiencies

Orphanet: ⁵⁸

Rare immunological diseases

External Ids:

Disease Ontology ¹¹ DOID:635

MeSH ⁴³ D000163

NCIt ⁴⁹ C2851

SNOMED-CT ⁶⁸ 62479008

ICD10 ³¹ B20

UMLS via Orphanet ⁷² C0001175

Orphanet ⁵⁸ ORPHA310050

ICD11 ³³ 1709907983 609223181 609223181/other more

UMLS ⁷¹ C0001175

Sources

Summaries for Acquired Immunodeficiency Syndrome

CDC: ² HIV is a virus spread through certain body fluids that attacks the body's immune system, specifically the CD4 cells, often called T cells. Over time, HIV can destroy so many of these cells that the body can't fight off infections and disease. These special cells help the immune system fight off infections. Untreated, HIV reduces the number of CD4 cells (T cells) in the body. This damage to the immune system makes it harder and harder for the body to fight off infections and some other diseases. Opportunistic infections or cancers take advantage of a very weak immune system and signal that the person has AIDS. Learn more about the stages of HIV and how to know whether you have HIV.

MalaCards based summary: Acquired Immunodeficiency Syndrome, also known as acquired immune deficiency syndrome, is related to human immunodeficiency virus type 1 and aids dementia complex. An important gene associated with Acquired Immunodeficiency Syndrome is HCP5 (HLA Complex P5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ethambutol and Pyrazinamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and bone marrow, and related phenotypes are neoplasm and endocrine/exocrine gland

Disease Ontology: ¹¹ A Human immunodeficiency virus infectious disease that results in reduction in the numbers of CD4-bearing helper T cells below 200 per microliter of blood or 14% of all lymphocytes thereby rendering the subject highly vulnerable to life-threatening infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. Opportunistic infections are common in people with AIDS.

Sources

Related Diseases for Acquired Immunodeficiency Syndrome

Diseases related to Acquired Immunodeficiency Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2617)

#	Related Disease	Score	Top Affiliating Genes
1	human immunodeficiency virus type 1	33.2	ITIH4 IL2 IL10 IFNG HLA-B CD4
2	aids dementia complex	32.5	TNF ITIH4 B2M
3	oral hairy leukoplakia	32.5	ITIH4 IL10 CD4
4	dementia	32.5	TNF ITIH4 IL6 IL1B CCR5
5	ascaris lumbricoides infection	32.5	IL10 CD4 ALB
6	good syndrome	32.4	TNF IL6 IL10 CD4
7	pneumocystosis	32.3	TNF IL6 IL2 IL10 IFNG CD4
8	toxoplasmosis	32.3	TNF IL6 IL1B IL10 IFNG CCR5
9	immune system disease	32.2	TNF IL6 IL2 IL1B IL10 CD4
10	immune deficiency disease	32.1	TNF RN7SK NEAT1 ITIH4 IL6 IL2
11	histoplasmosis	32.1	TNF IFNG HLA-B CD4
12	cryptococcosis	32.1	TNF IL10 IFNG CSF2 CD4
13	human cytomegalovirus infection	32.1	TNF IL6 IL10 CD4
14	cytomegalovirus retinitis	32.0	TNF IL10 IFNG HLA-B CSF2 CD4
15	autonomic nervous system disease	32.0	TNF IL6 IL1B ALB
16	candidiasis	31.9	TNF IL6 IL2 IL1B IL10 IFNG
17	macs syndrome	31.9	TNF IL10 IFNG IFNA1 CD4
18	progressive multifocal leukoencephalopathy	31.9	TNF IL2 CD4 CCR5
19	pneumonia	31.9	TNF IL6 IL1B IL10 IFNG CSF2
20	encephalitis	31.8	TNF ITIH4 IL6 IL1B IL10 IFNA1
21	cryptosporidiosis	31.8	TNF IFNG CD4
22	viral infectious disease	31.8	TNF ITIH4 IL6 IL2 IL1B IL10
23	oral candidiasis	31.8	IL6 CD4 B2M
24	cryptococcal meningitis	31.8	TNF IL6 IL2 IL10 IFNG CSF2
25	meningitis	31.8	TNF IL6 IL2 IL1B IL10 IFNG
26	esophagitis	31.7	TNF IL6 IL1B IL10
27	diarrhea	31.7	TNF IL6 IL2 IL1B IL10 IFNG
28	aspergillosis	31.7	TNF IL6 IL1B IL10 IFNG CSF2
29	lymphopenia	31.7	IL6 IL2 IL10 IFNG
30	vasculitis	31.7	TNF IL6 IL1B IL10 HLA-B
31	spinal cord disease	31.6	TNF IL6 IL10 CD4 ALB
32	chickenpox	31.6	TNF IL6 IL2 IL1B IL10 IFNG
33	retinal detachment	31.6	TNF IL6 IL10 IFNG
34	syphilis	31.6	TNF CD4 CCR5 B2M ALB
35	miliary tuberculosis	31.6	TNF IL2 IL10 IFNG CD4 ALB
36	herpes zoster	31.5	IL2 IL10 IFNG IFNA1 HLA-B HCP5
37	myelitis	31.5	TNF IL6 IL10
38	respiratory failure	31.5	TNF IL6 IL2 IL1B IL10 IFNG
39	myocarditis	31.5	TNF IL6 IL2 IL1B IL10 IFNG
40	uveitis	31.5	TNF IL6 IL2 IL1B IL10 IFNG
41	pancytopenia	31.5	IL6 IFNG CSF2 CD4 ALB
42	neutropenia	31.5	TNF IL6 IL2 IL1B IL10 IFNG
43	aplastic anemia	31.5	TNF IL6 IL1B IL10 IFNG CSF2
44	cholangitis	31.5	TNF IL6 IL2 IL10 HLA-B CCR5
45	pericardial effusion	31.5	TNF IL6 CD4 ALB
46	pericarditis	31.4	TNF IL6 IL1B IFNG
47	lymphoma, non-hodgkin, familial	31.4	IL6 IL2 CSF2 CD4 B2M
48	human immunodeficiency virus infectious disease	31.4	TNF ITIH4 IL2 IL10 IFNG IFNA1
49	exanthem	31.4	TNF IL6 IL2 IL1B IL10 IFNG
50	acute retinal necrosis syndrome	31.4	TNF IL6 IL10 CD4

Graphical network of the top 20 diseases related to Acquired Immunodeficiency Syndrome:

Sources

Symptoms & Phenotypes for Acquired Immunodeficiency Syndrome

MGI Mouse Phenotypes related to Acquired Immunodeficiency Syndrome:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.29	ALB B2M CCR2 CCR5 CSF2 IFNG
2	endocrine/exocrine gland	MP:0005379	10.23	ALB B2M CD4 CSF2 HLA-B IFNG
3	cellular	MP:0005384	10.22	ALB B2M CCR2 CCR5 CD4 CSF2
4	digestive/alimentary	MP:0005381	10.21	ALB B2M CCR2 CCR5 CD4 HLA-B
5	liver/biliary system	MP:0005370	10.18	ALB B2M CCR2 CCR5 IFNG IL10
6	immune system	MP:0005387	10.17	ALB B2M CCR2 CCR5 CD4 CSF2
7	cardiovascular system	MP:0005385	10.15	ALB B2M CCR2 CCR5 CSF2 HLA-B
8	no phenotypic analysis	MP:0003012	10.04	CCR2 CD4 HLA-B IFNG IL10 IL2
9	hematopoietic system	MP:0005397	9.97	B2M CCR2 CCR5 CD4 CSF2 HLA-B
10	respiratory system	MP:0005388	9.91	CCR2 CCR5 CSF2 IFNA1 IFNG IL10
11	mortality/aging	MP:0010768	9.83	ALB B2M CCR2 CCR5 CD4 CSF2
12	integument	MP:0010771	9.32	B2M CD4 CSF2 IFNG IL10 IL1B

Sources

Drugs & Therapeutics for Acquired Immunodeficiency Syndrome

Drugs for Acquired Immunodeficiency Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 643)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ethambutol

Approved

Phase 4

74-55-5, 1070-11-7

3279 14052

Pyrazinamide

Approved, Investigational

Phase 4

98-96-4

1046

Isoniazid

Approved, Investigational

Phase 4

54-85-3

3767

Foscarnet

Approved

Phase 4

63585-09-1, 4428-95-9

3415

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Didanosine

Approved

Phase 4

69655-05-6

50599

Rifabutin

Approved, Investigational

Phase 4

72559-06-9

46783538 6323490

Elvitegravir

Approved

Phase 4

697761-98-1

23083982 5277135

Lopinavir

Approved

Phase 4

192725-17-0

92727

Nevirapine

Approved

Phase 4

129618-40-2

4463

Amprenavir

Approved, Investigational

Phase 4

161814-49-9

65016

Aminosalicylic acid

Approved

Phase 4

65-49-6

4649

Mesalazine

Approved

Phase 4

89-57-6

4075

Fosamprenavir

Approved

Phase 4

226700-79-4

131536

Sofosbuvir

Approved

Phase 4

1190307-88-0

45375808

Estradiol

Approved, Investigational, Vet_approved

Phase 4

50-28-2

5757

Polyestradiol phosphate

Approved

Phase 4

28014-46-2

Carbamide peroxide

Approved

Phase 4

124-43-6

Mupirocin

Approved, Investigational, Vet_approved

Phase 4

12650-69-0

446596

Stavudine

Approved, Investigational

Phase 4

3056-17-5

18283

Rifamycin

Approved, Investigational

Phase 4

6998-60-3

6324616

Peginterferon alfa-2a

Approved, Investigational

Phase 4

198153-51-4

Enfuvirtide

Approved, Investigational

Phase 4

159519-65-0

16130199

Atorvastatin

Approved

Phase 4

134523-00-5

60823

Velpatasvir

Approved, Investigational

Phase 4

1377049-84-7

77335690 67683363

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

3640 5754

Pyrimethamine

Approved, Investigational, Vet_approved

Phase 4

58-14-0, 19085-09-7

4993

Sulfadiazine

Approved, Investigational, Vet_approved

Phase 4

68-35-9

5215

Bleomycin

Approved, Investigational

Phase 4

9041-93-4, 11056-06-7

5360373

Sulfadoxine

Approved, Investigational

Phase 4

2447-57-6

17134

Ethinylestradiol

Approved

Phase 4

57-63-6

5991

Rivastigmine

Approved, Investigational

Phase 4

123441-03-2

77991

Lithium carbonate

Approved

Phase 4

554-13-2

Citalopram

Approved

Phase 4

59729-32-7, 59729-33-8

2771

Desipramine

Approved, Investigational

Phase 4

50-47-5

2995

Oxandrolone

Approved, Investigational

Phase 4

53-39-4

5878

Buprenorphine

Approved, Illicit, Investigational, Vet_approved

Phase 4

52485-79-7, 53152-21-9

644073 40400

Methadone

Approved

Phase 4

76-99-3, 1095-90-5

4095

Cathine

Approved, Experimental, Illicit, Vet_approved, Withdrawn

Phase 4

14838-15-4, 492-39-7

131954576 4786 26934

Guaifenesin

Approved, Investigational, Vet_approved

Phase 4

93-14-1

3516

Naloxone

Approved, Vet_approved

Phase 4

465-65-6

5284596

Nicotine

Approved

Phase 4

54-11-5

942 89594

Bupropion

Approved

Phase 4

31677-93-7, 34841-39-9, 34911-55-2

444

Metamfetamine

Approved, Illicit, Withdrawn

Phase 4

537-46-2

10836

Etonogestrel

Approved, Investigational

Phase 4

54048-10-1

6917715

Rifapentine

Approved, Investigational

Phase 4

61379-65-5

5462354

Medroxyprogesterone acetate

Approved, Investigational

Phase 4

520-85-4, 71-58-9

6279 10631

Levonorgestrel

Approved, Investigational

Phase 4

797-63-7

13109

Interventional clinical trials:

(show top 50) (show all 2611)

#	Name	Status	NCT ID	Phase	Drugs
1	Boosted PI VS. NNRTI Based Therapy as Initial Treatment for HIV-1 Infected Patients With Advanced Disease	Unknown status	NCT00162643	Phase 4	zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
2	A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART	Unknown status	NCT01230580	Phase 4	Protease Inhibitor;Standard-of-care Antiretroviral therapy
3	A Prospective, Single Arm, Open-label 96 Week Observational Trial of the Tolerability, Adherence and Efficacy of a Dolutegravir/Abacavir/Lamivudine Single Tablet Regimen in HIV-1 Antibody Positive People Living With HIV With a History of Injection Drug Use Switching From Existing ART or Starting Treatment After Discontinuation of ART	Unknown status	NCT02659761	Phase 4	dolutegravir/abacavir/lamivudine
4	Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus	Unknown status	NCT00797030	Phase 4	cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
5	Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan	Unknown status	NCT03855176	Phase 4	Vaqta Injectable Product
6	Multicenter, Open, Pilot Clinical Trial Aimed to Compare the Efficacy of RAL1200 QD vs DRV-cb 800-150 QD Both in Combination With TAF/FTC in Patients With HIV Infection and CD4 Count Under 200 Cells/microL	Unknown status	NCT03842488	Phase 4	Experimental: RAL QD;Active comparator: DRV/cb
7	Empiric Treatment for Suspected Acute HIV Infection in the Emergency Department	Unknown status	NCT03711253	Phase 4	Bictegravir 50mg+Tenofovir AF 25 mg+emtricitabine 200 mg
8	Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome	Unknown status	NCT02686853	Phase 4	Liposomal amphotericin B
9	A Phase IV, Multicenter, Open and Randomized Study to Assess the Impact of the Change From Antiretroviral Treatment From Dual Therapy to Triple Therapy on Inflammation in Patients With Type 1 HIV Infection. InSTINCT Study	Unknown status	NCT04076423	Phase 4	Dual Therapy;Triple therapy
10	Impact of HIV-1 and Aging on Mucosal Vaccine Responses	Unknown status	NCT03729778	Phase 4
11	Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach	Unknown status	NCT01875952	Phase 4	Isoniazid
12	Prospective Pilot Study of the Efficacy, Safety and Tolerability of Bictegravir-Based HIV ART Same-Day Treatment Evaluations (B-HASTE)	Unknown status	NCT04249037	Phase 4	bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF);Standard initiation of antiretroviral therapy (ART)
13	Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Marginalized Populations Who Are Virologically Suppressed	Unknown status	NCT04132674	Phase 4	Bictegravir/emtricitabine/tenofovir alafenamide
14	Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring	Unknown status	NCT00836212	Phase 4	Reducing dose of Lopinavir;Reducing dose of efavirenz
15	Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients	Unknown status	NCT00872417	Phase 4	first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
16	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial).	Unknown status	NCT02337322	Phase 4	Dolutegravir;Darunavir/r
17	A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily	Unknown status	NCT00214435	Phase 4	once daily minimum 3-drug regimen of anti-retroviral medications
18	Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B	Unknown status	NCT03120494	Phase 4	Emtricitabine and Tenofovir
19	The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness	Unknown status	NCT01264510	Phase 4
20	An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings	Unknown status	NCT00124358	Phase 4	Buprenorphine
21	A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients.	Unknown status	NCT01013987	Phase 4	maraviroc;Raltegravir;Darunavir/ritonavir
22	Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study	Unknown status	NCT03549312	Phase 4	Genvoya;Epclusa;Biktarvy
23	Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults	Unknown status	NCT01782950	Phase 4	Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
24	A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea	Completed	NCT04192487	Phase 4	Crofelemer delayed-release tablets 125mg
25	An Open-Label Study of Nevirapine Plus Combivir® (ZDV+3TC) Treatment in Women Who Have Previously Received a Nevirapine Regimen for the Prevention of Mother to Child Transmission (pMTCT) of HIV-1.	Completed	NCT00144157	Phase 4	Nevirapine;Zidovudine;3TC
26	Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana	Completed	NCT01086878	Phase 4	cotrimoxazole
27	A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy	Completed	NCT00273988	Phase 4	nevirapine
28	Mesalamine to Reduce T Cell Activation in HIV Infection	Completed	NCT01090102	Phase 4	Mesalamine (5-aminosalicylic acid, Apriso);Placebo
29	Fluconazole Prophylaxis of Thrush in AIDS	Completed	NCT00001542	Phase 4	fluconazole
30	A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.	Completed	NCT02348177	Phase 4	lopinavir with ritonavir in 1:1 ratio;Lopinavir/ritonavir 4:1
31	Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia	Completed	NCT02396979	Phase 4	Methadone
32	Biomarkers for Event-driven PrEP Adherence	Completed	NCT04298697	Phase 4	TDF/FTC Dose Schedule for Arm A;TDF/FTC Dose Schedule for Arm B
33	A Personalized mHealth Approach to Smoking Cessation for Veterans Living With HIV (CDA 17-005)	Completed	NCT04135937	Phase 4	Bupropion;Varenicline;Nicotine Replacement Therapy
34	Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation	Completed	NCT03314064	Phase 4	Dolutegravir 50 mg
35	Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial	Completed	NCT00795717	Phase 4	Lovaza;Placebo
36	An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function	Completed	NCT00717067	Phase 4	Maraviroc;Ritonavir;Saquinavir
37	Phase IV, Single-center, Open Study to Evaluate the Benefits of the Start of Immediate Treatment Without Immunovirological Data ("Same Day Treatment") Compared to Conventional Treatment With BIC / FTC / TAF (Bictegravir/Emtricitabina/Tenofovir) in Naive Patients With Type 1 HIV (Human Immunodeficiency Virus) Infection	Completed	NCT05606055	Phase 4	BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato
38	A Randomised Trial of Monitoring Practice and Induction Maintenance Drug Regimens in the Management of Antiretroviral Therapy in Children With HIV Infection in Africa	Completed	NCT02028676	Phase 4	Arm A: ABC+3TC+NNRTI;Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance;Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance;Once-daily ABC+3TC;Twice-daily ABC+3TC;Continued cotrimoxazole prophylaxis
39	An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects	Completed	NCT02634073	Phase 4	Lamivudine;Sorbitol
40	Strategic Timing of AntiRetroviral Treatment	Completed	NCT00867048	Phase 4	All licensed antiretroviral medications
41	A Randomized, Controlled Trial Assessing the Effects of Raltegravir Intensification on Endothelial Function in Treated HIV Infection	Completed	NCT00843713	Phase 4	raltegravir;Placebo
42	Intranasal Mupirocin to Eliminate Carriage of Staphylococcus Aureus in HIV Infection	Completed	NCT00801879	Phase 4	Mupirocin calcium ointment, 2%;Placebo ointment
43	Randomized, Multi-Center, Phase IV, Comparative Study to Assess the Efficacy and Safety of Combined Peg-Interferon Alpha-2a (40 kD) With Ribavirin Combined Therapy for 48 or 72 Weeks of Treatment and 24 Weeks of Follow-Up in Patients With Chronic Hepatitis C, Genotype 1, Co-Infected With Human Immunodeficiency Virus	Completed	NCT02761629	Phase 4	Peg-Interferon Alpha-2A;Ribavirin
44	An Open-Label Safety Trial of Enfuvirtide (T-20/RO 29-9800, HIV-1 Fusion Inhibitor) in Combination With Free Choice Antiviral Regimen in Thai Patients With Advanced HIV Infection	Completed	NCT02582983	Phase 4	Enfuvirtide
45	Study of Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz in Antiretroviral-Naive, HIV-1 Infected Adult Subjects	Completed	NCT00549198	Phase 4	Abacavir/lamivudine and efavirenz;Tenofovir/Emtricitabine and efavirenz
46	Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART	Completed	NCT01869634	Phase 4	darunavir with ritonavir and fixed-dose viread+emtricitabine daily
47	A Randomized Comparative Clinical Trial of ZDV + 3TC + ABC (Trizivir) vs Monotherapy With Lopinavir/R (Kaletra) in Patients With Viral Suppression on Previous Treatment With ZDV + 3TC + ABC (Trizivir) for Preventing Lipoatrophy	Completed	NCT00865475	Phase 4	AZT+3TC+ABV (Trizivir);Switching to LPV/r monotherapy (Kaletra)
48	A Phase IV-III Comparative, Randomized, Open-label Study to Evaluate the Efficacy for the Recovery of Peripheral Fat (or of the Extremities) of Lopinavir/Ritonavir in Monotherapy Versus Abacavir/Lamivudine and Lopinavir/Ritonavir	Completed	NCT00865007	Phase 4	Monotherapy (Lopinavir/ritonavir);Monotherapy (Lopinavir/ritonavir) + ABC/3TC
49	Treatment of Acute Hepatitis C Virus in HIV Co-Infection	Completed	NCT00845676	Phase 4	Pegylated interferon alfa-2a + Ribavirin
50	Lopinavir/r Plus Saquinavir Salvage Therapy in HIV-infected Children With NRTI and/or NNRTI Failure: PK and Two-year Treatment Follow up	Completed	NCT00476359	Phase 4	Lopinavir/r plus saquinavir

Search NIH Clinical Center for Acquired Immunodeficiency Syndrome

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

abacavir

abacavir sulfate

Amprenavir

Delavirdine

Delavirdine Mesylate

Didanosine

efavirenz

enfuvirtide

Immunoglobulins, Intravenous

Indinavir

Indinavir Sulfate

Lamivudine

lopinavir

Nelfinavir

Nelfinavir Mesylate

Nevirapine

Ritonavir

Saquinavir

saquinavir mesylate

Stavudine

Tenofovir

tenofovir alafenamide fumarate

Tenofovir disoproxil fumarate

Zalcitabine

Zidovudine

Cochrane evidence based reviews: acquired immunodeficiency syndrome

Sources

Genetic Tests for Acquired Immunodeficiency Syndrome

Sources

Anatomical Context for Acquired Immunodeficiency Syndrome

Organs/tissues related to Acquired Immunodeficiency Syndrome:

MalaCards : T Cells, Breast, Bone Marrow, Lymph Node, Brain, Liver, Bone

Sources

Publications for Acquired Immunodeficiency Syndrome

Articles related to Acquired Immunodeficiency Syndrome:

(show top 50) (show all 49505)

#	Title	Authors	PMID	Year
1	Effects of marriage equality legislation on sexual health of the US population. ⁶²	Nikolaou D	36165350	2023
2	Short-term exposure to ambient particulate matter and mortality among HIV/AIDS patients: Case-crossover evidence from all counties of Hubei province, China. ⁶²	Zhang F...Zhu W	36257445	2023
3	High prevalence of vitamin D deficiency in HIV-infected individuals in comparison with the general population across Punjab province, Pakistan. ⁶²	Kanwal W...Rehman A	36387030	2023
4	Cachexia Is Associated With Adverse Outcomes in Patients Admitted With Heart Failure. ⁶²	Mohamad Alahmad MA...Gupta K	36343443	2023
5	U.S. Leading Causes of Death and Years of Potential Life Lost, 1981-2019: Implications for Surgical Research. ⁶²	Wang A...Xiang H	35945037	2023
6	Short-Term Administration of HIV Protease Inhibitor Saquinavir Improves Skull Bone Healing with Enhanced Osteoclastogenesis. ⁶²	Liu H...Wang D	36112847	2022
7	FBXO34 promotes latent HIV-1 activation by post-transcriptional modulation. ⁶²	Yang X...Zhu H	36285453	2022
8	International Validation of a Methicillin-Resistant Staphylococcus aureus Risk Assessment Tool for Skin and Soft Tissue Infections. ⁶²	Zasowski EJ...Rybak MJ	36319943	2022
9	Detection of Bartonella vinsonii subsp. berkhoffii in an HIV patient using metagenomic Next-Generation Sequencing. ⁶²	Shi Y...Ma X	35736664	2022
10	Novel 2-(Diphenylmethylidene) Malonic Acid Derivatives as Anti-HIV Agents: Molecular Modeling, Synthesis and Biological Evaluation. ⁶²	Lotfaliei M...Tabatabai SA	35765501	2022
11	HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis. ⁶²	Rashid A...Shao Y	35016590	2022
12	Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus. ⁶²	Boone B...Barnado A	36279805	2022
13	Evaluation of characteristic metabolites of aromatic amino acids in patients with HIV infection at different stages of disease. ⁶²	Yuan ZW...Zhang J	36464783	2022
14	Risk factors for depressive symptoms by age group among human immunodeficiency virus-infected adults in Korea. ⁶²	Kang CR...Yang SJ	34612099	2022
15	Acquired immunodeficiency syndrome complicating calvarial tuberculosis. ⁶²	Jiang H...Jiang W	35710516	2022
16	Professional commitment and willingness to care for people living with HIV among undergraduate nursing students: The mediating role of empathy. ⁶²	Shi C...Cleofas JV	36306636	2022
17	Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication. ⁶²	Yu Y...Zhang C	35132924	2022
18	Changes and Treatment Prognosis of Aqueous Humor Cytokine Concentrations of Patients with Acquired Immune Deficiency Syndrome Complicated by Cytomegalovirus Retinitis. ⁶²	Kong W...Wei W	36378859	2022
19	Lymphopenia in sepsis-an acquired immunodeficiency? ⁶²	Finfer S...Sasson SC	36468797	2022
20	Antiretroviral Therapy Management in Adults With HIV During ICU Admission. ⁶²	Walker CK...Claborn MK	33858244	2022
21	Atypical Presentation of Progressive Disseminated Histoplasmosis in a Patient Recently Diagnosed with Acquired Immunodeficiency Syndrome (AIDS). ⁶²	Stefan AJ...Tariq Z	36462572	2022
22	Pituitary Abscess Causing Hypopituitarism in a Patient With Acquired Immunodeficiency Syndrome. ⁶²	Warda F...Shahla L	36447827	2022
23	Ocular toxoplasmosis in a patient with acquired immunodeficiency syndrome. ⁶²	Chang CH...Hsu SM	36395783	2022
24	Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)-associated lymphomas. ⁶²	Sengar M...Bagal B	36323643	2022
25	Dupilumab for the treatment of adult atopic dermatitis in special populations. ⁶²	Patruno C...Napolitano M	35829641	2022
26	Oral and maxillofacial manifestations of human immunodefficiency virus infection. ⁶²	Benslama L	35618625	2022
27	Comprehensive HIV/AIDS knowledge and safer sex negotiation among adolescent girls and young women in sub-Saharan Africa. ⁶²	Frimpong JB...Ahinkorah BO	34558397	2022
28	Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion. ⁶²	Chan YT...Kamarulzaman A	36359329	2022
29	Prediction of HIV-1 protease cleavage site from octapeptide sequence information using selected classifiers and hybrid descriptors. ⁶²	Onah E...Ibezim A	36344934	2022
30	Spatial analysis of the AIDS mortality rate among young people in a province of the Brazilian Amazon: An ecological study. ⁶²	Lago Sousa SM...Pinheiro Botelho E	36468598	2022
31	Molecular Dynamics Study on Selected Bioactive Phytochemicals as Potential Inhibitors of HIV-1 Subtype C Protease. ⁶²	Shode FO...Govender KK	36422295	2022
32	The Medication Experience of TB/HIV Coinfected Patients: Qualitative Study. ⁶²	Resende NH...Mendonca SAM	36429870	2022
33	Association of asthma and herpes zoster, the role of vaccination: A literature review. ⁶²	Shrestha AB...Shrestha S	36301037	2022
34	Microfluidic Devices for HIV Diagnosis and Monitoring at Point-of-Care (POC) Settings. ⁶²	Tharakan S...Ilyas A	36354458	2022
35	[Fatal neurological side effect of anti-CD20 antibody treatment]. ⁶²	Schmidt K...Gro?mann A	36422661	2022
36	Spatial variability of mother-to-child human immunodeficiency virus transmission in a province in the Brazilian Rainforest: An ecological study. ⁶²	Quadros Santos MM...Pinheiro Botelho E	36468599	2022
37	Neuropsychological deficits associated with medical conditions: Implications for psychological services in criminal legal settings. ⁶²	Hunter S...Elbogen EB	35298234	2022
38	Fungal esophagitis associated with tuberculous pericarditis in an human immunodeficiency virus-positive patient: a case report. ⁶²	Silva GM...de Lima-Neto RG	36345027	2022
39	Kaposi Varicelliform Eruption With Contact Dermatitis in a Person Living with AIDS. ⁶²	Yuan LF...Lun WH	36113460	2022
40	Could Vhavenda initiation schools be a panacea for HIV and AIDS management in the Vhembe district of South Africa? ⁶²	Ndou-Mammbona AA...Mavhandu-Mudzusi AH	36453819	2022
41	Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study. ⁶²	Fenley JC...Junqueira JC	36354676	2022
42	Grief at the Heart of the Opioid Overdose Crisis: Past Lessons and Present Implications. ⁶²	Morford KL...Tetrault JM	35165230	2022
43	Consolidated Overview of Notifiable Adverse Events in the U.S. President's Emergency Plan for AIDS Relief's Voluntary Medical Male Circumcision Program Through 2020. ⁶²	Lucas T...Toledo C	36348185	2022
44	Hearing more to hear less: a scoping review of hearing aids for tinnitus relief. ⁶²	Jacquemin L...Shekhawat GS	34865589	2022
45	Patterns of HIV or AIDS Mortality Among Older People From 1990 to 2019 in China: Age-Period-Cohort Analysis. ⁶²	Ren N...Fan S	36394944	2022
46	Strengths and Challenges of Implementing a Learning Collaborative in the Ryan White HIV/AIDS Program. ⁶²	Evans L...Young SR	34142596	2022
47	Sexual Enrichment Aids: A Mixed Methods Study Evaluating Use, Hygiene, and Risk Perception among Women. ⁶²	Collar AL...Frietze KM	34919465	2022
48	Comprehensive HIV/AIDS knowledge and HIV testing among men in sub-Saharan Africa: a multilevel modelling. ⁶²	Tetteh JK...Seidu AA	34736542	2022
49	Attrition rate and its predictors among adults receiving anti-retroviral therapy following the implementation of the "Universal Test and Treat strategy" at public health institutions in Northern Ethiopia. A retrospective follow-up study. ⁶²	Bantie B...Dessie G	36411907	2022
50	Survival time and predictors of death among HIV infected under five children after initiation of anti -retroviral therapy in West Amhara Referral Hospitals, Northwest Ethiopia. ⁶²	Alemu GG...Achamyeleh AA	36411424	2022

Sources

Genes for Acquired Immunodeficiency Syndrome

Genes related to Acquired Immunodeficiency Syndrome (0 elite genes):

(show top 50) (show all 65)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	HCP5	HLA Complex P5	RNA Gene	155.6	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	18684101 19935381 20534626
2	NRON	Non-Coding Repressor Of NFAT	RNA Gene	154.25	Experimental evidence ³⁷ DISEASES inferred ¹⁴	25728138
3	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	153.88	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴	23362321
4	RN7SL1	RNA Component Of Signal Recognition Particle 7SL1	RNA Gene	152.94	Experimental evidence ³⁷ DISEASES inferred ¹⁴	16489186 20926562
5	RN7SK	RNA Component Of 7SK Nuclear Ribonucleoprotein	RNA Gene	150	Experimental evidence: Interaction ³⁷	17671421 20471949 20976203 (more) 21087998 21098020 22377309
6	CD4	CD4 Molecule	Protein Coding	20.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
7	CCR5	C-C Motif Chemokine Receptor 5	Protein Coding	19.35	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
8	ITIH4	Inter-Alpha-Trypsin Inhibitor Heavy Chain 4	Protein Coding	18.48	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
9	TNF	Tumor Necrosis Factor	Protein Coding	17.21	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
10	IL2	Interleukin 2	Protein Coding	17.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
11	HLA-B	Major Histocompatibility Complex, Class I, B	Protein Coding	16.93	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
12	IL6	Interleukin 6	Protein Coding	16.91	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
13	IL10	Interleukin 10	Protein Coding	16.88	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	IFNA1	Interferon Alpha 1	Protein Coding	16.55	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
15	IFNG	Interferon Gamma	Protein Coding	16.51	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	ALB	Albumin	Protein Coding	16.3	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	IL1B	Interleukin 1 Beta	Protein Coding	16.16	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	CCR2	C-C Motif Chemokine Receptor 2	Protein Coding	16.11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	CSF2	Colony Stimulating Factor 2	Protein Coding	16.11	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	B2M	Beta-2-Microglobulin	Protein Coding	16.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	CCL3	C-C Motif Chemokine Ligand 3	Protein Coding	15.93	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	CD38	CD38 Molecule	Protein Coding	15.57	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
23	FCGR3A	Fc Gamma Receptor IIIa	Protein Coding	15.46	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
24	IL15	Interleukin 15	Protein Coding	15.36	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
25	CRP	C-Reactive Protein	Protein Coding	15.18	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
26	CD40LG	CD40 Ligand	Protein Coding	15.06	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
27	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	15.04	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
28	TP53	Tumor Protein P53	Protein Coding	14.83	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
29	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	14.72	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
30	BCL2	BCL2 Apoptosis Regulator	Protein Coding	14.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
31	CD163	CD163 Molecule	Protein Coding	14.65	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
32	CD34	CD34 Molecule	Protein Coding	14.63	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
33	ICAM1	Intercellular Adhesion Molecule 1	Protein Coding	14.63	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
34	EPO	Erythropoietin	Protein Coding	14.59	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
35	BCL6	BCL6 Transcription Repressor	Protein Coding	14.54	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
36	CD9	CD9 Molecule	Protein Coding	14.5	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
37	IFNA2	Interferon Alpha 2	Protein Coding	14.48	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
38	CASP1	Caspase 1	Protein Coding	14.35	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
39	CXCR5	C-X-C Motif Chemokine Receptor 5	Protein Coding	14.21	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
40	TNFRSF1A	TNF Receptor Superfamily Member 1A	Protein Coding	14.16	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
41	ADA	Adenosine Deaminase	Protein Coding	14.05	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
42	ITGAM	Integrin Subunit Alpha M	Protein Coding	13.9	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
43	NCR1	Natural Cytotoxicity Triggering Receptor 1	Protein Coding	13.9	DISEASES inferred ¹⁴ GeneCards inferred via : Summaries (show sections)
44	CR2	Complement C3d Receptor 2	Protein Coding	13.89	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
45	VCAM1	Vascular Cell Adhesion Molecule 1	Protein Coding	13.89	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
46	IGF1	Insulin Like Growth Factor 1	Protein Coding	13.88	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
47	PECAM1	Platelet And Endothelial Cell Adhesion Molecule 1	Protein Coding	13.83	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
48	CD79A	CD79a Molecule	Protein Coding	13.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
49	APOE	Apolipoprotein E	Protein Coding	13.72	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
50	NOS2	Nitric Oxide Synthase 2	Protein Coding	13.43	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Acquired Immunodeficiency Syndrome

Sources

Expression for Acquired Immunodeficiency Syndrome

Search GEO for disease gene expression data for Acquired Immunodeficiency Syndrome.

Sources

Pathways for Acquired Immunodeficiency Syndrome

Pathways related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 69)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	14.03	B2M CCR2 CCR5 CD4 CSF2 HLA-B
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.85	CCR2 CCR5 CD4 CSF2 IL10 IL1B
3	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.68	CCR2 CCR5 CD4 CSF2 IFNA1 IFNG
4	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.57	TNF IL6 IL2 IL1B IL10 IFNG
5	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.48	CCR2 CCR5 CD4 CSF2 IL10 IL1B
6	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.37	CCR2 CCR5 CD4 CSF2 IL10 IL1B
7	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.26	B2M CCR2 CCR5 CD4 CSF2 HLA-B
8	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.86	TNF IL6 IL2 IL1B IFNA1
9	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.71	CCR5 CD4 IFNG IL1B TNF
10	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.7	TNF IL6 IL2 IL1B IL10 IFNG
11	NF-kappaB Signaling ³	12.66	TNF IL2 IL1B IL10 IFNG IFNA1
12	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.66	CCR2 CCR5 HLA-B IFNA1 IFNG IL10
13	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.53	TNF IL6 IL1B IFNA1
14	Bacterial infections in CF airways ²² Show member pathways Altered glycosylation of MUC1 in tumor microenvironment ⁷⁴ IL-1 beta-dependent CFTR expression ²² IL1-mediated signaling events ⁶¹ Immune response Bacterial infections in normal airways ²² Immune response TLR signaling pathways ²² NTHi-Induced Signaling ⁶⁴ Signal transduction through IL1R ⁷⁴	12.43	TNF IL6 IL1B IFNG
15	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.34	TNF IL6 IL1B IFNG
16	Immune response CD16 signaling in NK cells ²² Show member pathways Immune response Role of DAP12 receptors in NK cells ²²	12.29	TNF IL2 IFNG HLA-B CSF2
17	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.26	TNF IL2 IL10 IFNG CSF2 CD4
18	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	12.21	TNF IL6 IL1B IL10
19	Neuroinflammation and glutamatergic signaling ⁷⁴	12.21	TNF IL6 IL1B IL10 IFNG
20	Spinal cord injury ⁷⁴	12.12	TNF IL6 IL2 IL1B IFNG CCR2
21	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	12.1	IL2 IL1B IFNG CD4 CCR5 B2M
22	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	12.04	TNF IL6 IL2 IL10 IFNG CSF2
23	Interleukin-4 and Interleukin-13 signaling ⁶⁶	12.03	IL10 IL1B IL6 TNF
24	Allograft rejection ⁷⁴	12	HLA-B IFNG IL10 IL1B IL2 TNF
25	CCL18 signaling pathway ⁷⁴	11.97	IL6 IL10 CCR5 CCR2
26	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.95	IL6 IL1B IFNG CD4
27	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.95	TNF IL6 IL2 IL1B IL10 IFNG
28	Innate Lymphoid Cells Differentiation ⁶⁵	11.92	TNF IL2 IL1B IL10 IFNG CD4
29	Interferon Pathway ⁶⁴	11.88	IL6 IFNG IFNA1
30	Glucocorticoid receptor regulatory network ⁶¹	11.87	IL6 IL2 IFNG CSF2
31	Acute viral myocarditis ⁷⁴	11.86	CCR5 CD4 IFNG IL10 IL2 IL6
32	AP-1 transcription factor network ⁶¹	11.85	CSF2 IFNG IL10 IL2 IL6
33	Th17 cell differentiation pathway ⁷⁴	11.85	CD4 IFNG IL1B IL2 IL6
34	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.82	TNF NEAT1 IL6 IL2 IL10 IFNG
35	Activation of NF-KappaB by PKR ⁶⁴ Show member pathways Canonical NF-kB pathway ⁷⁴ Cellular Transformation by HTLV1 ⁶⁴ Inhibition of PKR ⁶⁶ STING pathway in Kawasaki-like disease and COVID-19 ⁷⁴	11.81	TNF IL1B IFNG
36	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.8	TNF IL2 IFNG CSF2
37	Lung fibrosis ⁷⁴	11.8	TNF IL6 IL1B CSF2 CCR2
38	Burn wound healing ⁷⁴	11.78	TNF IL6 IL1B
39	IL 10 signaling pathway ⁶⁷	11.77	TNF IL6 IL1B IL10
40	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.76	IFNG IL10 IL2 IL6 TNF
41	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.75	TNF IL6 IL2 IL1B IFNG CSF2
42	miRNAs involvement in the immune response in sepsis ⁷⁴	11.69	TNF IL6 IL10
43	MSP-RON Signaling ⁶⁴	11.64	TNF IL1B IFNG CCR2
44	THC Differentiation Pathway ⁶⁴	11.64	TNF IL2 IL10 IFNG CD4
45	SHP2 signaling ⁶¹	11.63	IL6 IL2 IFNG
46	Th2 Differentiation ⁶⁵	11.62	IL2 IL10 IFNG CD4
47	SARS-CoV-2 innate immunity evasion and cell-specific immune response ⁷⁴	11.6	TNF IL10 CSF2
48	Non-genomic actions of 1,25 dihydroxyvitamin D3 ⁷⁴	11.6	TNF IL6 IFNG
49	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	11.6	TNF IL6 IL1B IFNG
50	IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵ Show member pathways IL-2 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.52	TNF IL2 IL10 IFNG CSF2

Sources

GO Terms for Acquired Immunodeficiency Syndrome

Cellular components related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.64	TNF ITIH4 IL6 IL2 IL1B IL10

Biological processes related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show all 40)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of DNA-binding transcription factor activity	GO:0051091	10.27	TNF IL6 IL1B IL10
2	positive regulation of interleukin-6 production	GO:0032755	10.23	TNF IL6 IL1B IFNG
3	calcium-mediated signaling	GO:0019722	10.2	TNF CD4 CCR5 CCR2
4	positive regulation of type II interferon production	GO:0032729	10.17	TNF IL2 IL1B CCR2
5	receptor signaling pathway via JAK-STAT	GO:0007259	10.16	IFNG CSF2 CCR2
6	positive regulation of nitric oxide biosynthetic process	GO:0045429	10.15	TNF IL1B IFNG
7	negative regulation of extrinsic apoptotic signaling pathway in absence of ligand	GO:2001240	10.14	TNF IL1B CSF2
8	cellular response to lipopolysaccharide	GO:0071222	10.14	CCR5 CSF2 IL10 IL1B IL6 TNF
9	positive regulation of receptor signaling pathway via JAK-STAT	GO:0046427	10.13	TNF IL6 IL10
10	positive regulation of T cell activation	GO:0050870	10.13	CD4 CCR2 B2M
11	positive regulation of interleukin-2 production	GO:0032743	10.12	IL1B CD4 CCR2
12	liver regeneration	GO:0097421	10.1	TNF IL6 IL10
13	positive regulation of cytokine production	GO:0001819	10.1	IFNG IL10 IL1B TNF
14	regulation of insulin secretion	GO:0050796	10.1	IFNG IL1B IL6 TNF
15	positive regulation of immunoglobulin production	GO:0002639	10.08	IL10 IL2 IL6
16	macrophage differentiation	GO:0030225	10.07	IFNG CSF2 CD4
17	defense response	GO:0006952	10.06	CCR5 HLA-B IFNA1 TNF
18	positive regulation of glial cell proliferation	GO:0060252	10.02	TNF IL6 IL1B
19	positive regulation of chemokine production	GO:0032722	10.02	TNF IL6 IL1B IFNG
20	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	10.02	TNF IL6 IL2 IFNG CSF2
21	positive regulation of membrane protein ectodomain proteolysis	GO:0051044	10.01	TNF IL1B IFNG
22	positive regulation of heterotypic cell-cell adhesion	GO:0034116	10	TNF IL1B IL10
23	astrocyte activation	GO:0048143	9.99	TNF IL1B IFNG
24	positive regulation of NMDA glutamate receptor activity	GO:1904783	9.98	IFNG CCR2
25	negative regulation of cytokine production involved in immune response	GO:0002719	9.98	TNF IL10
26	positive regulation of fever generation	GO:0031622	9.97	TNF IL1B
27	negative regulation of neurogenesis	GO:0050768	9.97	TNF IL6 IL1B B2M
28	humoral immune response	GO:0006959	9.96	TNF IL6 IFNG IFNA1 CCR2
29	regulation of vascular endothelial growth factor production	GO:0010574	9.94	CCR2 IL6
30	sequestering of triglyceride	GO:0030730	9.94	IL1B TNF
31	positive regulation of synoviocyte proliferation	GO:1901647	9.93	NEAT1 TNF
32	positive regulation of neuroinflammatory response	GO:0150078	9.93	TNF IL6 IL1B
33	positive regulation of plasma cell differentiation	GO:1900100	9.92	IL2 IL10
34	positive regulation of nitrogen compound metabolic process	GO:0051173	9.91	TNF IFNG
35	vascular endothelial growth factor production	GO:0010573	9.91	TNF IL6 IL1B
36	positive regulation of vitamin D biosynthetic process	GO:0060557	9.88	TNF IFNG
37	chronic inflammatory response to antigenic stimulus	GO:0002439	9.88	TNF IL10
38	positive regulation of inflammatory response	GO:0050729	9.73	TNF NEAT1 IL2 IL1B IFNG CCR2
39	positive regulation of calcidiol 1-monooxygenase activity	GO:0060559	9.63	IFNG IL1B TNF
40	immune response	GO:0006955	9.6	TNF IL6 IL2 IL1B IL10 IFNG